U.S. Markets closed

Cystic Fibrosis Treatment for Fungal Infections in Lungs Reported

TAMPA, FL / ACCESSWIRE / September 28, 2016 / CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today describes a promising new treatment for fungal infections in the lungs of cystic fibrosis patients.

Up to half of these patients have infections in their lungs caused by a spore-forming mold named Aspergillus fumigatus. Many of those patients, particularly children and young adults, will develop an allergic reaction to the fungus, Bronchopulmonary Aspergillosis (ABPA), according to the Cystic Fibrosis Foundation. Coughing, wheezing and other symptoms can be severe.

Current treatments are oral drugs including itraconazole. The problem is that high doses are needed to get enough of the drug to the lungs. That causes severe side effects that must be managed and monitored-including liver toxicity.

A more effective strategy is to deliver the itraconazole directly to the lungs by breathing it in. That's the approach taken by Lexington, Mass-based pharmaceutical company Pulmatrix, Inc. (PULM). Pulmatrix's innovation was creating small, dense particles that can be easily inhaled, and combining them with drugs like itraconazole. Pulmatrix's drug candidate for CF is called PUR1900.

"We've urgently needed a way to deliver antifungal drugs directly to the lungs," said Stanford University CF expert Richard Moss M.D. "Pulmatrix's PUR1900, using the inhaled dry particle technology, meets that need. It could offer major benefits to CF patients with fungal infections."

That's why the U.S. Food & Drug Administration has granted the company's request for orphan drug status for PUR1900, explaining that the designation "is based on a plausible hypothesis that [the] drug may be clinically superior to the same drug that is already approved."

While PUR1900 has the potential to improve the lives of cystic fibrosis patients, especially children and young adults, it also could bring significant revenues for Pulmatrix. The estimated cystic fibrosis market alone is tens of thousands of patients a year, and the drug could also find much larger markets treating millions of other pulmonary fungal infections and other immunocompromised patients, making Pulmatrix a strong investment opportunity.

For more information on PUR1900 go to ir.pulmatrix.com and watch the video on https://www.youtube.com/watch?v=t8RgU8YUtjo.

Contact:

Bud Wayne
budwayne@ceocfomagazine.com

SOURCE: CEOCFO Magazine